Editorial: Window dressing
By Sacramento Bee,
Sacramento Bee
| 06. 23. 2005
Stem cell 'enhancements' won't do the job
As part of a closed-door deal with the state Senate, leaders of California's $3 billion stem cell institute have proposed some revisions to their weak policies on conflicts of interest, open meetings and public access to internal documents.
These proposals, while a step forward, are a mixed bag. On one hand, they don't go far enough in preventing $3 billion in public monies from being directed to interests with inside access at the Institute for Regenerative Medicine. On the other, they demonstrate that public pressure can prompt this agency to revisit how it does business.
The main issue centers on the out-of-state researchers and industry employees who will be recommending millions of dollars in stem cell research grants to California universities, nonprofits and industries.
Right now, the public knows the identities of these peer reviewers, but not whether they have side deals with biomedical firms or stock in Geron or other corporations interested in stem cell research. That's because the peer reviewers are not required to publicly disclose their economic interests, as do...
Related Articles
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Aleks Krotoski, The Guardian | 09.28.2025
Imagine you’re the leader of one of the most powerful nations in the world. You have everything you could want at your disposal: power, influence, money. But, the problem is, your time at the top is fleeting. I’m not...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...